MUNICH, July 17 — A gene expression profiling test that has become a standard tool in breast cancer treatment decisions works by measuring the activity of 21 genes from a single tumour sample, offering a numeric answer to a question that once required guesswork: does this patient need chemotherapy? The test, Oncotype DX, was developed by Genomic Health, Inc., a company founded in 2000. It calculates what is called a Recurrence Score on a scale from zero to 100.
That number quantifies the risk of distant recurrence in early-stage, hormone receptor-positive, HER2-negative breast cancer — a common subtype where the treatment calculus has historically been fraught. The technical reality is that the 21-gene panel is not a random assortment.
It includes proliferation genes such as Ki-67, hormone receptor genes including ER and PR, and invasion genes like MMP11, plus five reference genes for calibration. The result is a continuous variable, but clinical decision-making has settled on predefined cutoffs: a low score of 0-25 indicates low risk and minimal benefit from chemotherapy; a high score of 26-100 suggests higher risk and greater benefit from the drugs.
The validation history
The test was initially validated in the NSABP B-14 trial in 2004, then in the NSABP B-20 trial in 2006. But the detail that matters for current practice came from the TAILORx trial, published in the New England Journal of Medicine in 2018. That study prospectively validated the test in over 10,000 patients and confirmed that women with a Recurrence Score of 0-25 can safely avoid chemotherapy.
That is a significant finding. Chemotherapy carries substantial side effects, and for years clinicians lacked a precise tool to determine which patients would actually benefit.
The TAILORx data gave them one. The test is performed on formalin-fixed, paraffin-embedded tumour tissue, which is the standard way pathology labs preserve biopsy samples. That makes it widely accessible — no special handling, no frozen sections, no exotic logistics.
The sample that was already taken can be used.
Guidelines and adoption
Oncotype DX has been incorporated into major clinical guidelines, including those from the National Comprehensive Cancer Network and the American Society of Clinical Oncology. That means it is not a niche test used in a few academic centres; it is a recommended part of the workup for the relevant patient population across the United States and increasingly internationally. Under the hood, the test measures the activity of 16 cancer-related genes and five reference genes.
The reference genes serve as a control, allowing the assay to normalise for variations in tissue quality and sample handling. The cancer-related genes cover the biological pathways that drive tumour growth and hormone response.
As ever in oncology, the goal is to treat the patients who need treatment and spare those who do not. The Recurrence Score provides a quantitative framework for that decision. For patients with a low score, the evidence from TAILORx is clear: adding chemotherapy to endocrine therapy does not improve outcomes.
For those with a high score, the benefit is real enough to justify the toxicity. The test does not replace clinical judgement.
It adds a data point. But it is a data point backed by a prospective trial with over 10,000 participants, which is more evidence than many cancer tests ever receive. Consult your doctor for medical advice.
Sources
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “How Oncotype DX Works: The 21-Gene Recurrence Score Explained”, “description”: “MUNICH, July 17 — A gene expression profiling test that has become a standard tool in breast cancer treatment decisions works by measuring the activity…”, “datePublished”: “2026-07-17T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Sebastian Smith”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}, “citation”: [{“@type”: “CreativeWork”, “url”: “https://en.wikipedia.org/wiki/Gene_expression_profiling”}]}
